Sign in →

Test Code IBDP2 Inflammatory Bowel Disease Serology Panel, Serum


Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL Serum

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Useful For

Distinguishing between ulcerative colitis and Crohn disease in patients for whom the specific diagnosis is unclear based on endoscopic, pathologic, and imaging evaluations

 

This test is not useful for determining the extent of disease in patients with inflammatory bowel disease or determining the response to disease-specific therapy including surgical resection of diseased intestine.

Profile Information

Test ID Reporting Name Available Separately Always Performed
ANCA2 Cytoplasmic Neutrophilic Ab IBD, S No Yes
SCERA Saccharomyces cerevisiae Ab, IgA, S Yes Yes
SCERG Saccharomyces cerevisiae Ab, IgG, S Yes Yes

Method Name

ANCA2: Indirect Immunofluorescent Assay (IFA)

SCERA, SCERG: Enzyme-Linked Immunosorbent Assay (ELISA)

Reporting Name

Inflammatory Bowel Disease Panel, S

Specimen Type

Serum

Specimen Minimum Volume

Serum: 0.8 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 21 days
  Frozen  21 days

Reference Values

CYTOPLASMIC NEUTROPHIL ANTIBODIES, INFLAMMATORY BOWEL DISEASE PANEL, SERUM

Negative (not detectable)

 

SACCHAROMYCES CEREVISIAE ANTIBODY, IGA

Negative: <20.0 RU/mL

Positive: ≥20.0 RU/mL

 

SACCHAROMYCES CEREVISIAE ANTIBODY, IGG

Negative: <20.0 RU/mL

Positive: ≥20.0 RU/mL

Interpretation

The presence of antineutrophil cytoplasmic antibodies in the absence of IgA and IgG anti-Saccharomyces cerevisiae antibodies is consistent with the diagnosis of ulcerative colitis; the presence of IgA and IgG ASCA in the absence of ANCA is consistent with Crohn disease.

Clinical Reference

1. Rose NR, Mackay IR, eds. Inflammatory bowel diseases. In: The Autoimmune Diseases: Elsevier; 2008

2. Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: Management of Crohn's disease in adults. Am J Gastroenterol. 2025;120(6):1225-1264

3. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025;120(6):1187-1224

4. Clark C, Turner J. Diagnostic modalities for inflammatory bowel disease: Serologic markers and endoscopy. Surg Clin North Am. 2015;95(6):1123-1141

5. Zhou G, Song Y, Yang W, et al. ASCA, ANCA, ALCA and many more: Are they useful in the diagnosis of inflammatory bowel disease? Dig Dis. 2016;34(1-2):90-97. doi:10.1159/000442934

6. Sendid B, Cornu M, Cordier C, Bouckaert J, Colombel JF, Poulain D. From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health. Autoimmun Rev. 2024;23(2):103486

Day(s) Performed

Monday through Friday

Report Available

3 to 7 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86671 x 2

86036

LOINC Code Information

Test ID Test Order Name Order LOINC Value
IBDP2 Inflammatory Bowel Disease Panel, S 87551-8

 

Result ID Test Result Name Result LOINC Value
610030 Cytoplasmic Neutrophilic Ab IBD, S 17355-9
SCERA Saccharomyces cerevisiae Ab, IgA, S 47320-7
SCERG Saccharomyces cerevisiae Ab, IgG, S 47321-5
614542 ANCA2 Interpretation 49308-0

Forms

If not ordering electronically, complete, print, and send Gastroenterology and Hepatology Test Request (T728) with the specimen.